Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 670

1.

Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program.

Wegner S, Vann JJ, Liu G, Byrns P, Cypra C, Campbell W, Stiles A.

Pediatrics. 2004 Dec;114(6):1612-9.

PMID:
15574623
2.

Economic analysis of palivizumab in infants with congenital heart disease.

Yount LE, Mahle WT.

Pediatrics. 2004 Dec;114(6):1606-11.

PMID:
15574622
3.

Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis.

Lofland JH, O'Connor JP, Chatterton ML, Moxey ED, Paddock LE, Nash DB, Desai SA.

Clin Ther. 2000 Nov;22(11):1357-69.

PMID:
11117660
4.

Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis.

Stevens TP, Sinkin RA, Hall CB, Maniscalco WM, McConnochie KM.

Arch Pediatr Adolesc Med. 2000 Jan;154(1):55-61.

PMID:
10632251
5.

Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany.

Roeckl-Wiedmann I, Liese JG, Grill E, Fischer B, Carr D, Belohradsky BH.

Eur J Pediatr. 2003 Apr;162(4):237-44. Epub 2003 Feb 6.

PMID:
12647196
6.
7.

Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: potential for savings.

Marchetti A, Lau H, Magar R, Wang L, Devercelli G.

Clin Ther. 1999 Apr;21(4):752-66.

PMID:
10363740
8.

Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants.

Joffe S, Ray GT, Escobar GJ, Black SB, Lieu TA.

Pediatrics. 1999 Sep;104(3 Pt 1):419-27.

PMID:
10469764
9.

Comparison of the cost of hospitalization for respiratory syncytial virus disease versus palivizumab prophylaxis in Canadian Inuit infants.

Banerji A, Lanctôt KL, Paes BA, Masoud ST, Tam DY, Macdonald WA, Roberts A.

Pediatr Infect Dis J. 2009 Aug;28(8):702-6. doi: 10.1097/INF.0b013e31819df78e.

PMID:
19461555
11.

Cost-effectiveness of palivizumab in New Zealand.

Vogel AM, McKinlay MJ, Ashton T, Lennon DR, Harding JE, Pinnock R, Graham D, Grimwood K, Pattemore PK, Schousboe M.

J Paediatr Child Health. 2002 Aug;38(4):352-7.

PMID:
12173995
12.

Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada.

Paes B, Steele S, Janes M, Pinelli J.

Curr Med Res Opin. 2009 Jul;25(7):1585-91. doi: 10.1185/03007990902929112.

PMID:
19469698
13.

The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis .

Lanctôt KL, Masoud ST, Paes BA, Tarride JE, Chiu A, Hui C, Francis PL, Oh PI.

Curr Med Res Opin. 2008 Nov;24(11):3223-37. doi: 10.1185/03007990802484234 . Epub 2008 Oct 16.

PMID:
18928643
14.

Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.

Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, Quero J; IRIS Study Group.

Pediatr Infect Dis J. 2003 Sep;22(9):823-7.

PMID:
14506376
15.

Description of the outcomes of prior authorization of palivizumab for prevention of respiratory syncytial virus infection in a managed care organization.

Buckley BC, Roylance D, Mitchell MP, Patel SM, Cannon HE, Dunn JD.

J Manag Care Pharm. 2010 Jan-Feb;16(1):15-22.

16.

Reliability of medicaid claims versus medical record data: in a cost analysis of palivizumab.

Jacobson Vann J, Feaganes J, Wegner S.

Pharmacoeconomics. 2007;25(9):793-800.

PMID:
17803337
17.

Prophylaxis in RSV infection (Palivizumab)--is it worthwhile?

Hashmi NA, Cosgrove JF, MacMahon P.

Ir Med J. 2000 Dec;93(9):284.

PMID:
11209917
18.

Respiratory syncytial virus immune globulin: decisions and costs.

Barton LL, Grant KL, Lemen RJ.

Pediatr Pulmonol. 2001 Jul;32(1):20-8.

PMID:
11416872
19.

Hospital admission of high risk infants for respiratory syncytial virus infection: implications for palivizumab prophylaxis.

Heikkinen T, Valkonen H, Lehtonen L, Vainionpää R, Ruuskanen O.

Arch Dis Child Fetal Neonatal Ed. 2005 Jan;90(1):F64-8.

20.

Incidence of respiratory syncytial virus-related hospitalizations in high-risk children: follow-up of a national cohort of infants treated with Palivizumab as RSV prophylaxis.

Lacaze-Masmonteil T, Rozé JC, Fauroux B; French Pediatricians' Group of Sunagis Patients' Name-Based Programs.

Pediatr Pulmonol. 2002 Sep;34(3):181-8.

PMID:
12203846

Supplemental Content

Support Center